866-997-4948(US-Canada Toll Free)

B-Cell Chronic Lymphocytic Leukemia - Pipeline Review, H2 2013

Published By :

Global Markets Direct

Published Date : Oct 2013

Category :

Oncology

No. of Pages : 62 Pages


Global Markets Directs, \'B-Cell Chronic Lymphocytic Leukemia Pipeline Review, H2 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for B-Cell Chronic Lymphocytic Leukemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for B-Cell Chronic Lymphocytic Leukemia. B-Cell Chronic Lymphocytic Leukemia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for B-Cell Chronic Lymphocytic Leukemia.
  • A review of the B-Cell Chronic Lymphocytic Leukemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the B-Cell Chronic Lymphocytic Leukemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for B-Cell Chronic Lymphocytic Leukemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding B-Cell Chronic Lymphocytic Leukemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
B-Cell Chronic Lymphocytic Leukemia Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for B-Cell Chronic Lymphocytic Leukemia 8
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Development by Companies 10
B-Cell Chronic Lymphocytic Leukemia Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 13
Comparative Analysis 13
Early Clinical Stage Products 14
Comparative Analysis 14
Pre-Clinical Stage Products 15
Comparative Analysis 15
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Products under Development by Companies 16
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in B-Cell Chronic Lymphocytic Leukemia Therapeutics Development 18
GTC Biotherapeutics, Inc. 18
Nippon Shinyaku Co., Ltd. 19
Ono Pharmaceutical Co., Ltd. 20
MAT Biopharma 21
SBI Biotech Co., Ltd. 22
Advancell 23
B-Cell Chronic Lymphocytic Leukemia - Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Combination Products 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
navitoclax - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
acadesine - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
CNF-1010 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
bafetinib - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
TG-20 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
CD19 Specific T Cell - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
GNKG-168 - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Therapeutic Tumor Infiltrating Lymphocytes - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
MAT-304 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Vivia-009 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
ONO-4059 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Anti-CD19-CAR-Transduced T Cells - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Tumor-Derived Lymphocytes + Allogeneic Hematopoietic Stem Cell Transplantation - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Anti-APRIL - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
GNKS-356 - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Xanthone Derivatives For Cancer - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
TAB-08 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Central Memory T Cell Therapy For Cancer - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Drug Profile Updates 53
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Discontinued Products 55
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Dormant Products 56
B-Cell Chronic Lymphocytic Leukemia - Product Development Milestones 57
Featured News & Press Releases 57
Aug 24, 2012: TG Therapeutics Announces Poster Presentation For Ublituximab At 7th International Workshop On Waldenstrom\'s Macroglobulinemia 57
Dec 12, 2011: CytRx Announces Presentation Of Favorable Phase II Results With Bafetinib In Relapsed B-Cell Chronic Lymphocytic Leukemia At ASH Conference 57
Nov 15, 2011: TheraMAB launches Phase I clinical trial of first-in-class agonistic monoclonal antibody TAB08 in Russia 58
Jun 04, 2007: ZymoGenetics Reports Results From Atacicept Phase 1b Clinical Trial In B-Cell Chronic Lymphocytic Leukemia 59

Appendix 61
Methodology 61
Coverage 61
Secondary Research 61
Primary Research 61
Expert Panel Validation 61
Contact Us 62
Disclaimer 62

List of Table


Number of Products Under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2013 8
Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2013 9
Number of Products under Development by Companies, H2 2013 11
Number of Products under Investigation by Universities/Institutes, H2 2013 12
Comparative Analysis by Mid Clinical Stage Development, H2 2013 13
Comparative Analysis by Early Clinical Stage Development, H2 2013 14
Comparative Analysis by Pre-Clinical Stage Development, H2 2013 15
Products under Development by Companies, H2 2013 16
Products under Investigation by Universities/Institutes, H2 2013 17
GTC Biotherapeutics, Inc., H2 2013 18
Nippon Shinyaku Co., Ltd., H2 2013 19
Ono Pharmaceutical Co., Ltd., H2 2013 20
MAT Biopharma, H2 2013 21
SBI Biotech Co., Ltd., H2 2013 22
Advancell, H2 2013 23
Assessment by Monotherapy Products, H2 2013 24
Assessment by Combination Products, H2 2013 25
Assessment by Stage and Route of Administration, H2 2013 27
Assessment by Stage and Molecule Type, H2 2013 29
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Drug Profile Updates 53
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Discontinued Products 55
B-Cell Chronic Lymphocytic Leukemia Therapeutics - Dormant Products 56

List of Chart


Number of Products under Development for B-Cell Chronic Lymphocytic Leukemia, H2 2013 8
Products under Development for B-Cell Chronic Lymphocytic Leukemia - Comparative Analysis, H2 2013 9
Products under Development by Companies, H2 2013 10
Products under Investigation by Universities/Institutes, H2 2013 12
Mid Clinical Stage Products, H2 2013 13
Early Clinical Stage Products, H2 2013 14
Pre-Clinical Stage Products, H2 2013 15
Assessment by Monotherapy Products, H2 2013 24
Assessment by Combination Products, H2 2013 25
Assessment by Route of Administration, H2 2013 26
Assessment by Stage and Route of Administration, H2 2013 27
Assessment by Molecule Type, H2 2013 28
Assessment by Stage and Molecule Type, H2 2013 29

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *